Malignant choroid melanoma

Summary

Malignant choroid melanoma (MONDO:0003878) is a cancer (an umbrella term covering 5 Mondo subtypes) and 18 clinical trials. Top therapeutic interventions include belzupacap sarotalocan and (r,r)-tramadol. A subtype of uveal melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant choroid melanoma
Mondo ID	MONDO:0003878
DOID	DOID:6438
NCIT	C4561
SNOMED CT	255021005
UMLS	C0346388
MedGen	138064
GARD	0023710
Anatomy (UBERON)	UBERON:0001776
Is cancer (heuristic)	yes

Also known as: choroid malignant melanoma · choroid melanoma · choroidal melanoma · malignant melanoma of choroid · malignant melanoma of the choroid · melanoma (disease) of optic choroid · melanoma of choroid · melanoma of the choroid · optic choroid melanoma · optic choroid melanoma (disease)

Disease family

This is a subtype of uveal melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › uveal cancer › uveal melanoma › malignant choroid melanoma

Related subtypes (7): spindle cell intraocular melanoma, mixed cell uveal melanoma, posterior uveal melanoma, intermediate cell type uveal melanoma, iris melanoma, necrotic uveal melanoma, epithelioid cell uveal melanoma

Subtypes (5): choroid spindle cell melanoma, choroid mixed cell melanoma, intermediate cell type choroid melanoma, choroid epithelioid cell melanoma, choroid necrotic melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE1	3
PHASE3	2
PHASE1/PHASE2	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06007690	PHASE3	RECRUITING	A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT00680225	PHASE3	COMPLETED	Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
NCT00111046	PHASE1/PHASE2	UNKNOWN	Pain Relief - Tramadol Versus Ibuprofen
NCT01251978	PHASE2	COMPLETED	Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
NCT03052127	PHASE1/PHASE2	COMPLETED	Study in Subjects With Small Primary Choroidal Melanoma
NCT04417530	PHASE2	COMPLETED	Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
NCT00750399	PHASE1	COMPLETED	Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
NCT00765921	PHASE1	COMPLETED	Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
NCT03865212	PHASE1	TERMINATED	Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
NCT03941379	Not specified	ACTIVE_NOT_RECRUITING	A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
NCT07338968	Not specified	NOT_YET_RECRUITING	A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
NCT07421739	Not specified	RECRUITING	Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
NCT00344799	Not specified	COMPLETED	Cytogenetic Study of Ocular Melanoma
NCT00351728	Not specified	COMPLETED	Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone
NCT01253759	Not specified	COMPLETED	Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma
NCT01460810	Not specified	COMPLETED	Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma
NCT02875652	Not specified	COMPLETED	Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)
NCT05266430	Not specified	TERMINATED	Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BELZUPACAP SAROTALOCAN	3	3
(R,R)-TRAMADOL	0	1